Expand PTGX Menu
PTGX MENU

PTGX Latest Press Releases

-- July 16, 2026 --

Protagonist Therapeutics Reports Granting of Inducement Awards ACCESS Newswire 4:05 PM

-- July 1, 2026 --

Protagonist Therapeutics Reports Granting of Inducement Awards ACCESS Newswire 4:05 PM

-- June 16, 2026 --

Protagonist Therapeutics Reports Granting of Inducement Awards ACCESS Newswire 4:00 PM

-- June 1, 2026 --

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress ACCESS Newswire 7:05 AM

-- May 28, 2026 --

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 ACCESS Newswire 7:05 AM

-- May 5, 2026 --

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update ACCESS Newswire 4:05 PM

-- April 28, 2026 --

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration ACCESS Newswire 9:05 AM

-- April 16, 2026 --

Protagonist Therapeutics Reports Granting of Inducement Awards ACCESS Newswire 4:05 PM

-- March 28, 2026 --

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting ACCESS Newswire 10:05 AM

-- March 18, 2026 --

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis ACCESS Newswire 8:05 AM

-- March 2, 2026 --

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera Business Wire 2:00 AM
Market Data Delayed 15 Minutes